David Scholfield

438 total citations
21 papers, 336 citations indexed

About

David Scholfield is a scholar working on Urology, Rheumatology and Surgery. According to data from OpenAlex, David Scholfield has authored 21 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Urology, 10 papers in Rheumatology and 6 papers in Surgery. Recurrent topics in David Scholfield's work include Urinary Bladder and Prostate Research (11 papers), Pelvic floor disorders treatments (10 papers) and Urinary Tract Infections Management (5 papers). David Scholfield is often cited by papers focused on Urinary Bladder and Prostate Research (11 papers), Pelvic floor disorders treatments (10 papers) and Urinary Tract Infections Management (5 papers). David Scholfield collaborates with scholars based in United Kingdom, United States and Canada. David Scholfield's co-authors include Matthew Simms, M.C. Bishop, Amanda Darekar, Bimal Malhotra, Elizabeth R. Jacobs, Gary G. Kay, Paul Maruff, Alan C. Perkins, Jane Humphreys and Michael R. Price and has published in prestigious journals such as The Journal of Urology, British Journal of Cancer and British Journal of Urology.

In The Last Decade

David Scholfield

21 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Scholfield United Kingdom 10 155 127 79 54 53 21 336
Alison M. Cooper United Kingdom 6 159 1.0× 98 0.8× 34 0.4× 50 0.9× 38 0.7× 7 374
Mireille Grégoire Canada 9 234 1.5× 147 1.2× 96 1.2× 186 3.4× 11 0.2× 16 431
Pouya Javadian United States 12 33 0.2× 77 0.6× 75 0.9× 152 2.8× 7 0.1× 42 443
Fernando Vázquez‐Alonso Spain 11 37 0.2× 23 0.2× 41 0.5× 59 1.1× 12 0.2× 43 382
Daniela Oliveira Portugal 8 55 0.4× 99 0.8× 37 0.5× 131 2.4× 8 0.2× 36 358
Evangelos N. Symeonidis Greece 11 47 0.3× 38 0.3× 21 0.3× 67 1.2× 7 0.1× 45 358
H. Henry Lai Taiwan 7 147 0.9× 98 0.8× 81 1.0× 32 0.6× 6 0.1× 16 252
Yagil Barazani United States 8 43 0.3× 39 0.3× 58 0.7× 64 1.2× 4 0.1× 19 305
Paul Zupkas United States 12 306 2.0× 158 1.2× 149 1.9× 85 1.6× 3 0.1× 18 404
Sara Hogan United States 9 80 0.5× 23 0.2× 29 0.4× 19 0.4× 25 0.5× 29 292

Countries citing papers authored by David Scholfield

Since Specialization
Citations

This map shows the geographic impact of David Scholfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Scholfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Scholfield more than expected).

Fields of papers citing papers by David Scholfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Scholfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Scholfield. The network helps show where David Scholfield may publish in the future.

Co-authorship network of co-authors of David Scholfield

This figure shows the co-authorship network connecting the top 25 collaborators of David Scholfield. A scholar is included among the top collaborators of David Scholfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Scholfield. David Scholfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thadeio, Peter F., David Gruben, David Keller, et al.. (2021). Demographic diversity of participants in Pfizer sponsored clinical trials in the United States. Contemporary Clinical Trials. 106. 106421–106421. 32 indexed citations
2.
Grenabo, L., Sender Herschorn, Steven A. Kaplan, et al.. (2017). Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion. 33(10). 1731–1736. 3 indexed citations
3.
Darekar, Amanda, Martin Carlsson, Fady Ntanios, et al.. (2016). Development of a predictive model for urgency urinary incontinence. Contemporary Clinical Trials. 51. 44–49. 6 indexed citations
4.
Wagg, Adrian, Matthias Oelke, J.C. Angulo, David Scholfield, & Daniel Arumí. (2015). Review of the Efficacy and Safety of Fesoterodine for Treating Overactive Bladder and Urgency Urinary Incontinence in Elderly Patients. Drugs & Aging. 32(2). 103–125. 14 indexed citations
5.
Chapple, Christopher R., Matthias Oelke, Steven A. Kaplan, et al.. (2015). Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Current Medical Research and Opinion. 31(6). 1201–1243. 15 indexed citations
6.
Chapple, Christopher R., Tim Schneider, François Haab, et al.. (2014). Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial. British Journal of Urology. 114(3). 418–426. 28 indexed citations
7.
Klarskov, Niels, et al.. (2013). Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry. International Urogynecology Journal. 25(6). 755–760. 8 indexed citations
8.
Kay, Gary G., et al.. (2012). Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine. Postgraduate Medicine. 124(3). 7–15. 52 indexed citations
9.
Malhotra, Bimal, Ahmed El‐Tahtawy, Ellen Q. Wang, et al.. (2012). Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder. Journal of Pediatric Urology. 8(4). 336–342. 20 indexed citations
10.
Nickel, J. Curtis, Anna Crossland, Edward L. Davis, et al.. (2012). Investigation of a Ca 2+ Channel α2δ Ligand for the Treatment of Interstitial Cystitis: Results of a Randomized, Double-Blind, Placebo Controlled Phase II Trial. The Journal of Urology. 188(3). 817–823. 9 indexed citations
11.
Kay, Gary G., et al.. (2011). Evaluation of Cognitive Function in Healthy Older Adults Treated With Fesoterodine. Neurourology and Urodynamics. 30(6). 3 indexed citations
12.
Evans, Robert J., et al.. (2010). 1508 TANEZUMAB REDUCES PAIN AND URGENCY IN INTERSTITIAL CYSTITIS: RESULTS OF A PHASE 2 TRIAL. The Journal of Urology. 183(4S). 1 indexed citations
13.
14.
Klarskov, Niels, David Scholfield, Koshika Soma, et al.. (2008). EVALUATION OF THE SENSITIVITY OF URETHRAL PRESSURE REFLECTOMETRY (UPR) AND URETHRAL PRESSURE PROFILOMETRY (UPP) TO DETECT PHARMACOLOGICAL AUGMENTATION OF URETHRAL PRESSURE, USING [S,S]-REBOXETINE. The Journal of Urology. 179(4S). 521–522. 5 indexed citations
15.
16.
Scholfield, David, Matthew Simms, & M.C. Bishop. (2003). MUC1 mucin in urological malignancy. British Journal of Urology. 91(6). 560–566. 13 indexed citations
17.
Simms, Matthew, Andrea Murray, David Scholfield, et al.. (2001). Production and characterisation of a C595 antibody- 99m Tc conjugate for immunoscintigraphy of bladder cancer. Urological Research. 29(1). 13–19. 15 indexed citations
18.
Simms, Matthew, Alan C. Perkins, M.R. Price, David Scholfield, & M.C. Bishop. (2001). 99m Technetium‐C595 radioimmunoscintigraphy: a potential staging tool for bladder cancer. British Journal of Urology. 88(7). 686–691. 7 indexed citations
19.
Murray, Andrea, Matthew Simms, David Scholfield, et al.. (2001). Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer.. PubMed. 42(5). 726–32. 38 indexed citations
20.
Simms, Matthew, et al.. (2000). Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. British Journal of Cancer. 83(4). 443–446. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alison M. Cooper Breakdown of academic impact, for papers by Mireille Grégoire Breakdown of academic impact, for papers by Pouya Javadian Breakdown of academic impact, for papers by Fernando Vázquez‐Alonso Breakdown of academic impact, for papers by Daniela Oliveira Breakdown of academic impact, for papers by Evangelos N. Symeonidis Breakdown of academic impact, for papers by H. Henry Lai Breakdown of academic impact, for papers by Yagil Barazani Breakdown of academic impact, for papers by Paul Zupkas Breakdown of academic impact, for papers by Sara Hogan
Rankless by CCL
2026